25/06/2026
Today, our principal shareholders reaffirmed their confidence in Coegin by committing additional capital to support our continued commercialization and growth.
The financing solution combines a directed issue of approximately SEK 6.3 million with a capital facility providing access to an additional SEK 16 million, strengthening our financial flexibility through 2026–2027.
By combining a limited directed issue with a flexible capital facility from committed long-term shareholders, the financing provides the resources needed to execute our commercial strategy while promoting capital efficiency, minimizing financing costs and supporting long-term shareholder alignment.
This allows us to focus on:�✔️ Scaling production capacity�✔️ Accelerating commercial expansion�✔️ Supporting our growing network of partners�✔️ Driving towards positive cash flow
💬 Johan Arver, Alveco Invest AB:
"The Board has proposed a financing solution that we, as a principal shareholder, have chosen to fully support. We are not investing defensively – we are investing to accelerate growth. The Company has transitioned from development to commercialization, with innovations that stand out internationally and a highly scalable business model. We believe in the Company, we believe in the management team, and we see strong prospects for achieving positive cash flow within a foreseeable future."
As we continue executing our commercial strategy and delivering on our plans, we thank Alveco Invest AB, Crystallus AB, Bengt Svenstig and Lennart Börjesson for their continued confidence in Coegin Pharma.
Read more in our press release:
